AstraZeneca

LONDON, November 18, 2011 - AstraZeneca today announced that the Marketing Authorisation Application for CAPRELSA (vandetanib) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.

GENEVA, April 15, 2011 - Results from a large pan-European study suggest that up to 135,000 deaths from cardiovascular disease (CVD), such as heart attacks and strokes, could be prevented in Europe each year though better control of risk factors including high blood pressure, high cholesterol, smoking and diabetes.[1] This equates to one preventable death every four minutes.[1] The European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA) was a large public health study carried out in 12 European countries.

LONDON, January 27, 2011 - AstraZeneca said its full-year results had outperformed guidance, with growth in emerging markets compensating for patent expiries and pricing pressures from Western governments.

PRAGUE, November 8, 2010 - Cardiovascular disease (CVD) is the leading cause of death in Europe, killing an estimated 4.3 million people each year.[i] Results from a large pan-European study announced today indicate that many of these deaths could be avoided if at-risk patients received better preventative care.[ii] The European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA) estimated the proportion of deaths associated with risk factors for CVD, and assessed how well those risk factors are managed.

LONDON, October 22, 2010 - A post-hoc-analysis from JUPITER published in the European Heart Journal shows CRESTOR(TM) (rosuvastatin) 20 mg significantly reduced major cardiovascular (CV) events, defined as the combined end-point of CV death, stroke and myocardial infarction, compared to placebo, by 50% (p=0.028; CI 0.27-0.93) in high risk patients with a 10-year Framingham risk score >20% and by 43% in patients with an extrapolated SCORE risk greater than or equal to 5% (p=0.0003; CI 0.32-0.68).